UK markets closed

AtriCure, Inc. (ATRC)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
20.89-1.33 (-5.99%)
At close: 04:00PM EDT
21.52 +0.63 (+3.04%)
After hours: 07:52PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close22.22
Open22.83
Bid20.83 x 300
Ask20.90 x 100
Day's range20.78 - 23.01
52-week range20.19 - 59.61
Volume961,816
Avg. volume787,365
Market cap1.011B
Beta (5Y monthly)1.37
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • Business Wire

    AtriCure Reports First Quarter 2024 Financial Results

    MASON, Ohio, May 01, 2024--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2024 financial results.

  • Business Wire

    AtriCure to Participate in the 2024 Bank of America Securities Healthcare Conference

    MASON, Ohio, April 30, 2024--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Bank of America Securities Healthcare Conference.

  • Business Wire

    AtriCure Announces Launch of the cryoSPHERE®+ Probe for Post-Operative Pain Management

    MASON, Ohio, April 18, 2024--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has launched the cryoSPHERE®+ cryoablation probe, leveraging new insulation technology to reduce freeze times by 25% versus AtriCure’s legacy cryoSHPERE® device. The product is currently in an extended limited launch period in the United States, with